Founded by physician-scientists nearly 30 years ago, our science-driven approach has resulted in six FDA-approved medicines and numerous product candidates in a range of diseases, including cancer, asthma, pain and infectious diseases.
In addition to our medicines, our innovations include the VelociSuite® technologies, world-class manufacturing operations, one of the largest human sequencing efforts in the world and rapid response technologies being used for global good.
$331.97 2.93 (0.89)%
Market Cap 35.17B
06/22/18 4:00 PM ET | Minimum 20 minutes delay.
Stock information provided by eSignal.
Goldman Sachs 39th Annual Global Healthcare Conference
Jun 12, 2018 | 8:40 AM PT
Corporate Presentation - June 2018
Jun 12, 2018